| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0056 | 0.9 |
| mRNA | isoevodiamine | CTRPv2 | pan-cancer | AAC | 0.0056 | 0.9 |
| mRNA | QS11 | GDSC1000 | pan-cancer | AAC | -0.006 | 0.9 |
| mRNA | BHG712 | GDSC1000 | pan-cancer | AAC | 0.005 | 0.9 |
| mRNA | GSK4112 | CTRPv2 | pan-cancer | AAC | -0.0062 | 0.9 |
| mRNA | TW 37 | GDSC1000 | pan-cancer | AAC | -0.0055 | 0.9 |
| mRNA | FQI-1 | CTRPv2 | pan-cancer | AAC | -0.0077 | 0.9 |
| mRNA | istradefylline | CTRPv2 | pan-cancer | AAC | -0.009 | 0.9 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.0064 | 0.9 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | -0.0067 | 0.9 |